E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/26/2018 in the Prospect News Structured Products Daily.

New Issue: Credit Suisse sells $1.92 million contingent coupon callable yield notes on ETFs

By Wendy Van Sickle

Columbus, Ohio, Oct. 26 – Credit Suisse AG, London Branch priced $1.92 million of contingent coupon callable yield notes due Oct. 26, 2021 linked to the lesser performing of the SPDR S&P Biotech ETF and the Technology Select Sector SPDR fund, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will pay a quarterly contingent coupon at an annual rate of 10.6% if each fund closes at or above its coupon barrier, 70% of its initial level, on the observation date for that quarter.

Starting on May 13, 2019, Credit Suisse may redeem the notes at par on any quarterly contingent coupon payment date.

The payout at maturity will be par unless either fund closes below its 70% knock-in level, in which case investors will be fully exposed to any losses of the least-performing fund.

Credit Suisse Securities (USA) LLC is the agent.

Issuer:Credit Suisse AG, London Branch
Issue:Contingent coupon callable yield notes
Underlying funds:SPDR S&P Biotech ETF and Technology Select Sector SPDR fund
Amount:$1,919,000
Maturity:Oct. 26, 2021
Coupon:10.6% per year, payable quarterly if each fund closes at or above its coupon barrier on the quarterly observation date
Price:Par
Payout at maturity:Par unless either fund finishes below its 70% knock-in level, in which case full exposure to the losses of the least-performing fund
Call:Starting May 13, 2019, on any contingent coupon payment date at par
Initial prices:$85.42 for biotech ETF, $70.01 for technology fund
Coupon barrier levels:$59.794 for biotech ETF, $49.007 for technology fund; 70% of initial levels
Knock-in levels:$59.794 for biotech ETF, $49.007 for technology fund; 70% of initial levels
Pricing date:Oct. 19
Settlement date:Oct. 26
Agent:Credit Suisse Securities (USA) LLC
Fees:0%
Cusip:22551LE89

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.